D
Sell
2/7/2025Upgraded
Mineralys Therapeutics, Inc. (MLYS) was upgraded to D- from E+ on 2/7/2025 due to an increase in the volatility index.
E
Sell
1/23/2025Downgrade
Mineralys Therapeutics, Inc. (MLYS) was downgraded to E+ from D- on 1/23/2025 due to a decline in the volatility index and total return index.
D
Sell
1/6/2025Upgraded
Mineralys Therapeutics, Inc. (MLYS) was upgraded to D- from E+ on 1/6/2025 due to an increase in the total return index, volatility index and valuation index.
E
Sell
11/8/2024Downgrade
Mineralys Therapeutics, Inc. (MLYS) was downgraded to E+ from D- on 11/8/2024 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 17.63 to 10.96.
D
Sell
2/15/2024Upgraded
Mineralys Therapeutics, Inc. (MLYS) was upgraded to D- from E+ on 2/15/2024 due to an increase in the volatility index.
E
Sell
11/9/2023Downgrade
Mineralys Therapeutics, Inc. (MLYS) was downgraded to E+ from D- on 11/9/2023 due to a major decline in the efficiency index, volatility index and solvency index. Net income declined 87.46% from -$12.14M to -$22.76M, the quick ratio declined from 42.06 to 18.74, and total capital declined 7.37% from $285.01M to $264.01M.
D
Sell
11/1/2023Upgraded
Mineralys Therapeutics, Inc. (MLYS) was upgraded to D- from E on 11/1/2023 due to an increase in the volatility index, growth index and valuation index. Earnings per share increased from -$0.51 to -$0.31.
E
Sell
8/1/2023Upgraded
Mineralys Therapeutics, Inc. (MLYS) was upgraded to E from E- on 8/1/2023 due to an increase in the total return index.
E
Sell
5/22/2023None
Mineralys Therapeutics, Inc. (MLYS) was downgraded to E- from U on 05/22/2023.
